BioSpace News Archive

The World Health Organization announced in this week’s WHO Weekly Epidemiological Record that Malawi has been validated to have eliminated lymphatic filariasis as a public health problem.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced positive topline data from the Company’s AURORA randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial of avacopan for the treatment of the chronic disabling skin disease Hidradenitis Suppurativa (HS)

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces financial results for the third quarter of 2020.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced revenue of $244.0 million for the quarter ended September 30, 2020,

Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2020.

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced the appointment of Nancy L. Snyderman, M.D., to its Board of Directors.

Gilead Sciences, Inc. announced that the company’s Board of Directors has declared a cash dividend of $0.68 per share of common stock for the fourth quarter of 2020.

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2020

Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”), expand the product licenses, and revise the license payment schedule. Acura’s LIMITx™ technology, when applied to any pharmace

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2020.